Discovery of 1,3-diaminobenzenes as selective inhibitors of platelet activation at the PAR1 receptor

ACS Medicinal Chemistry Letters

Volumn 3, Issue 3, 2012, Pages 232-237

  Dockendorff, Chris ^a   Aisiku, Omozuanvbo ^b   Verplank, Lynn ^a   Dilks, James R ^b   Smith, Daniel A ^b   Gunnink, Susanna F ^b   Dowal, Louisa ^b   Negri, Joseph ^a   Palmer, Michelle ^a   MacPherson, Lawrence ^a   Schreiber, Stuart L ^a   Flaumenhaft, Robert ^b  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

1,3 diaminobenzene; allosteric inhibitor; ML161; MLPCN MLSMR; PAR1 inhibitor; platelet activation

Indexed keywords

1,3 PHENYLENEDIAMINE; ATOPAXAR; PROTEINASE ACTIVATED RECEPTOR 1; VORAPAXAR;

ARTICLE; BRAIN HEMORRHAGE; CONTROLLED STUDY; DRUG STABILITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

EID: 84863247932     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml2002696     Document Type: Article

References (25)

1. For a review, see, for example: Michelson, A. D. Antiplatelet therapies for the treatment of cardiovascular disease Nature Rev. Drug Discovery 2010, 9, 154-169
2. See, for example: Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. 2002, 324, 71-86.
3. See, for example: Wiviott, S. D. Prasugrel versus clopidogrel in patients with acute coronary syndromes N. Engl. J. Med. 2007, 357, 2001-2015 (Pubitemid 350106708)
4. Discovery of SCH 530348: Chackalamannil, S.; Wang, Y.; Greenlee, W. J.; Hu, Z.; Xia, Y.; Ahn, H.-S.; Boykow, G.; Hsieh, Y.; Palamanda, J.; Agans-Fantuzzi, J.; Kurowski, S.; Graziano, M.; Chintala, M. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity J. Med. Chem. 2008, 51, 3061-3064 (Pubitemid 351821864)
5. Tricoci, P. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes N. Engl. J Med. 2012, 366, 20-33
6. Goto, S.; Ogawa, H.; Takeuchi, M.; Flather, M. D.; Bhatt, D. L. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease Eur. Heart J. 2010, 31, 2601-2613
7. O'Donoghue, M. L. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial Circulation 2011, 123, 1843-1853
8. Wiviott, S. D.; Flather, M. D.; O’Donoghue, M. L.; Goto, S.; Fitzgerald, D. J.; Cura, F.; Aylward, P.; Guetta, V.; Dudek, D.; Contant, C. F.; Angiolillo, D. J.; Bhatt, D. L. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: The lessons from antagonizing the cellular effect of Thrombin-Coronary Artery Disease Trial Circulation 2011, 123, 1854-1863
9. Kato, Y.; Kita, Y.; Nishio, M.; Hirasawa, Y.; Ito, K.; Yamanaka, T.; Motoyama, Y.; Seki, J. In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist Eur. J. Pharmacol. 1999, 384, 197-202 (Pubitemid 30006956)
10. Andrade-Gordon, P.; Maryanoff, B. E.; Derian, C. K.; Zhang, H. C.; Addo, M. F.; Darrow, A. L.; Eckardt, A. J.; Hoekstra, W. J.; McComsey, D. F.; Oksenberg, D.; Reynolds, E. E.; Santulli, R. J.; Scarborough, R. M.; Smith, C. E.; White, K. B. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 12257-12262 (Pubitemid 29513488)
11. Ahn, H.-S.; Boykow, G.; Burnett, D. A.; Caplen, M. A.; Czarniecki, M.; Domalski, M. S.; Foster, C.; Manna, M.; Stamford, A. W.; Wu, Y. Structure-activity relationships of pyrroloquinazolines as thrombin receptor antagonists Bioorg. Med. Chem. Lett. 1999, 9, 2073-2078 (Pubitemid 29336404)
12. Nantermet, P. G.; Barrow, J. C.; Lundell, G. F.; Pellicore, J. M.; Rittle, K. E.; Young, M.; Freidinger, R. M.; Connolly, T. M.; Condra, C.; Karczewski, J.; Bednar, R. A.; Gaul, S. L.; Gould, R. J.; Prendergast, K.; Selnick, H. G. Discovery of a nonpeptidic small molecule antagonist of the human platelet thrombin receptor (PAR-1) Bioorg. Med. Chem. Lett. 2002, 12, 319-323 (Pubitemid 34113893)
13. Perez, M. Discovery of novel protease activated receptors 1 antagonists with potent antithrombotic activity in vivo J. Med. Chem. 2009, 52, 5826-5836
14. VerPlank, L.; Dockendorff, C.; Negri, J.; Perez, J. R.; Dilks, J.; MacPherson, L.; Palmer, M.; Flaumenhaft, R.; Schreiber, S. L. Probe reports from the NIH Molecular Libraries Program. Chemical Genetic Analysis of Platelet Granule Secretionî - ̧Probe 3, 2010; https://mli.nih.gov/mli/?dl-id= 1254.
15. Flaumenhaft, R.; Sim, D. S. The platelet as a model for chemical genetics Chem. Biol. 2003, 10, 481-486 (Pubitemid 36774634)
16. Flaumenhaft, R.; Dilks, J. R. Discovery-based strategies for studying platelet function Mini Rev. Med Chem. 2008, 8, 350-357 (Pubitemid 351606776)
17. Sim, D. S.; Merrill-Skoloff, G.; Furie, B. C.; Furie, B.; Flaumenhaft, R. Initial accumulation of platelets during arterial thrombus formation in vivo is inhibited by elevation of basal cAMP levels Blood 2004, 103, 2127-2134 (Pubitemid 38326229)
18. Review: Furie, B.; Furie, B. C.; Flaumenhaft, R. A journey with platelet P-selectin: The molecular basis of granule secretion, signalling and cell adhesion Thromb. Haemostasis 2001, 86, 214-221 (Pubitemid 32666187)
19. At the present time, compound 4 (ML161) is also commercially available from ChemBridge Corp.
20. Review: Chen, C.; Maryanoff, B. E.; Andrade-Gordon, P. Thrombin receptor modulators: Medicinal chemistry, biological evaluation, and clinical application. In Thrombin: Physiology and Disease; Maragoudakis, M.; Tsopanoglou, N., Eds.; Springer: New York, NY, 2009; pp 205-236.
21. Review: Chackalamannil, S. Thrombin receptor (Protease Activated Receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects J. Med. Chem. 2006, 49, 5389-5403 (Pubitemid 44373171)
22. The serine protease thrombin cleaves the N terminus of PAR1, which then acts as a tethered ligand to activate signaling through intramolecular ligation of the ortherosteric binding site. SFLLRN peptide is derived from this tethered ligand and is an agonist of PAR1 when applied externally. For the initial discovery, see Vu, T.-K. H.; Hung, D. T.; Wheaton, V. I.; Coughlin, S. R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation Cell 1991, 64, 1057-1068 (Pubitemid 121001193)
23. Serebruany, V. L.; Kogushi, M.; Dastros-Pitei, D.; Flather, M.; Bhatt, D. L. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease Thromb. Haemostasis 2009, 102, 111-119
24. Dowal, L.; Sim, D. S.; Dilks, J. R.; Blair, P.; Beaudry, S.; Denker, B. M.; Koukos, G.; Kuliopulos, A.; Flaumenhaft, R. Identification of an antithrombotic allosteric modulator that acts through helix 8 of PAR1 Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 2951-2956
25. For a discussion, see Dowal, L.; Flaumenhaft, R. Targeting platelet G-Protein Coupled Receptors (GPCRs): Looking beyond conventional GPCR antagonism Curr. Vasc. Pharmacol. 2010, 8, 140-154